TSC-203 HLA-A*02:01 is under clinical development by TScan Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TSC-203 HLA-A*02:01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TSC-203 HLA-A*02:01 overview

TSC-203 is under development for the treatment of head and neck cancer, cervical cancer, melanoma, anal cancer, ovarian cancer and non-small cell lung cancer. The therapeutic candidate comprises T-cells genetically engineered to express T-cell receptor (TCR) targeting cells expressing melanoma antigen preferentially expressed in tumors (PRAME). It is being developed based on the TScan platform technology.

TScan Therapeutics overview

TScan Therapeutics (TCR) provides life-changing T cell therapies for patients. It is headquartered in Boston, Massachusetts, the US.

For a complete picture of TSC-203 HLA-A*02:01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.